Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Gene Voss who wrote (5194)	2/1/1998 12:39:00 PM
From: RT	Read Replies (1) \| Respond to of 23519

Gene, I may be confused on this patent issue so please help me out. Since HVSF has received a patent for their product, does it not indicate that the patent office has already concluded that it does NOT infringe on Vivus's patent. Secondly, on the surface does it not appear that HVSF may have a superior delivery system as well as a superior product. Finally, if Vivus is unsuccessful in defending its patent against HVSF would you not be concerned that HVSF may become the product of choice for the transurethral delivery market.. Gene, in one of your earlier posts, you mentioned that Vivus may have other obstacles but not HVSF. What obstacles are you suggesting? Thanks in advance for the help. RT PS. Now get back to work and put the finishing touches on your new IMPROVED SUPERMUSE.